Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ricardo RibasSunil PancholiAradhana RaniEugene SchusterStephanie K GuestJoanna Nikitorowicz-BuniakNikiana SimigdalaAllan ThornhillFrancesca Avogadri-ConnorsRichard E CutlerAlshad S LalaniMitch DowsettStephen R JohnstonLesley-Ann MartinPublished in: Breast cancer research : BCR (2018)
Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER.